Key Disease Characteristics Influencing the Choice Between ICI + TKI and ICI + ICI Regimens in mRCC
Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.
- What specific disease characteristics most strongly influence your choice between immune checkpoint inhibitor plus tyrosine kinase inhibitor and immune checkpoint inhibitor plus immune checkpoint inhibitor regimens?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
McGregor and Participants Discuss Impact of Drug Efficacy and Histology on nccRCC Care
October 17th 2024During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
Read More
